诺诚健华发布2025年第一季度报告。报告期内,总收入同比增长129.9%,达到3.8亿元。其中,奥布替尼当季同比增长89.2%,达到3.1亿元。对于这份业绩,你怎么看?TIGIT研发再遭打击。5月13日,因为在II期肺癌试验中未达预期疗效,GSK与iTeos Therapeutics宣布终止TIGIT抗体belrestotug研发。百济神州向全资子公司发行1.33亿股日前,百济神州公告表示,经公司...
Source Link诺诚健华发布2025年第一季度报告。报告期内,总收入同比增长129.9%,达到3.8亿元。其中,奥布替尼当季同比增长89.2%,达到3.1亿元。对于这份业绩,你怎么看?TIGIT研发再遭打击。5月13日,因为在II期肺癌试验中未达预期疗效,GSK与iTeos Therapeutics宣布终止TIGIT抗体belrestotug研发。百济神州向全资子公司发行1.33亿股日前,百济神州公告表示,经公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.